419 related articles for article (PubMed ID: 22104275)
1. Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.
Scott R; Donoghoe M; Watts GF; O'Brien R; Pardy C; Taskinen MR; Davis TM; Colman PG; Manning P; Fulcher G; Keech AC;
Cardiovasc Diabetol; 2011 Nov; 10():102. PubMed ID: 22104275
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
[TBL] [Abstract][Full Text] [Related]
3. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Scott R; O'Brien R; Fulcher G; Pardy C; D'Emden M; Tse D; Taskinen MR; Ehnholm C; Keech A;
Diabetes Care; 2009 Mar; 32(3):493-8. PubMed ID: 18984774
[TBL] [Abstract][Full Text] [Related]
4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of premorbid metabolic syndrome in Spanish adult workers using IDF and ATPIII diagnostic criteria: relationship with cardiovascular risk factors.
Tauler P; Bennasar-Veny M; Morales-Asencio JM; Lopez-Gonzalez AA; Vicente-Herrero T; De Pedro-Gomez J; Royo V; Pericas-Beltran J; Aguilo A
PLoS One; 2014; 9(2):e89281. PubMed ID: 24586656
[TBL] [Abstract][Full Text] [Related]
6. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography.
Saely CH; Koch L; Schmid F; Marte T; Aczel S; Langer P; Hoefle G; Drexel H
Diabetes Care; 2006 Apr; 29(4):901-7. PubMed ID: 16567835
[TBL] [Abstract][Full Text] [Related]
7. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.
Ucar E; Huzmeli C; Guven O; Savas N; Gullu M; Asilyoruk S; Kuvandik C; Temizkan A; Kuvandik G
Ren Fail; 2009; 31(3):221-8. PubMed ID: 19288328
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
[TBL] [Abstract][Full Text] [Related]
9. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
10. Index of central obesity as a parameter to replace waist circumference for the definition of metabolic syndrome in predicting cardiovascular disease.
Luo W; Guo Z; Wu M; Hao C; Zhou Z; Yao X
J Cardiovasc Med (Hagerstown); 2014 Oct; 15(10):738-44. PubMed ID: 24937473
[TBL] [Abstract][Full Text] [Related]
11. Performance of two metabolic syndrome definitions in the estimation of cardiovascular disease among hypertensive patients.
Hirota AH; Rodrigues CJ; Borges RL; Ribeiro AB; Zanella MT; Batista MC
J Clin Hypertens (Greenwich); 2010 Aug; 12(8):588-96. PubMed ID: 20695935
[TBL] [Abstract][Full Text] [Related]
12. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Rajamani K; Colman PG; Li LP; Best JD; Voysey M; D'Emden MC; Laakso M; Baker JR; Keech AC;
Lancet; 2009 May; 373(9677):1780-8. PubMed ID: 19465233
[TBL] [Abstract][Full Text] [Related]
13. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns.
Wang J; Ruotsalainen S; Moilanen L; Lepistö P; Laakso M; Kuusisto J
Eur Heart J; 2007 Apr; 28(7):857-64. PubMed ID: 17303589
[TBL] [Abstract][Full Text] [Related]
14. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
15. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events.
Mancia G; Bombelli M; Facchetti R; Casati A; Ronchi I; Quarti-Trevano F; Arenare F; Grassi G; Sega R
J Hypertens; 2010 May; 28(5):999-1006. PubMed ID: 20308922
[TBL] [Abstract][Full Text] [Related]
16. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.
Bonora E; Targher G; Formentini G; Calcaterra F; Lombardi S; Marini F; Zenari L; Saggiani F; Poli M; Perbellini S; Raffaelli A; Gemma L; Santi L; Bonadonna RC; Muggeo M
Diabet Med; 2004 Jan; 21(1):52-8. PubMed ID: 14706054
[TBL] [Abstract][Full Text] [Related]
17. The Prevalence of Metabolic Syndrome and Its Components among Type 2 Diabetes Mellitus Patients at a Tertiary Hospital, Northwest Ethiopia.
Biadgo B; Melak T; Ambachew S; Baynes HW; Limenih MA; Jaleta KN; Tachebele B; Melku M; Abebe M
Ethiop J Health Sci; 2018 Sep; 28(5):645-654. PubMed ID: 30607080
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of metabolic syndrome in type 2 diabetes mellitus using NCEP-ATPIII, IDF and WHO definition and its agreement in Gwalior Chambal region of Central India.
Yadav D; Mahajan S; Subramanian SK; Bisen PS; Chung CH; Prasad GB
Glob J Health Sci; 2013 Sep; 5(6):142-55. PubMed ID: 24171882
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the International Diabetes Federation definition of metabolic syndrome in Chinese patients older than 30 years and diagnosed with type 2 diabetes mellitus.
Lu B; Yang Y; Song X; Dong X; Zhang Z; Zhou L; Li Y; Zhao N; Zhu X; Hu R
Metabolism; 2006 Aug; 55(8):1088-96. PubMed ID: 16839846
[TBL] [Abstract][Full Text] [Related]
20. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project.
Vishram JK; Borglykke A; Andreasen AH; Jeppesen J; Ibsen H; Jørgensen T; Palmieri L; Giampaoli S; Donfrancesco C; Kee F; Mancia G; Cesana G; Kuulasmaa K; Salomaa V; Sans S; Ferrieres J; Dallongeville J; Söderberg S; Arveiler D; Wagner A; Tunstall-Pedoe H; Drygas W; Olsen MH;
PLoS One; 2014; 9(9):e107294. PubMed ID: 25244618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
